MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical’s sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and...

Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st Annual Scientific Sessions Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...

Nemaura Medical Issues Letter to Shareholders Following April 28 Shareholder Update Call Loughborough, England, April 29, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...